BR9911564A - Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto - Google Patents

Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto

Info

Publication number
BR9911564A
BR9911564A BR9911564-6A BR9911564A BR9911564A BR 9911564 A BR9911564 A BR 9911564A BR 9911564 A BR9911564 A BR 9911564A BR 9911564 A BR9911564 A BR 9911564A
Authority
BR
Brazil
Prior art keywords
compound
releasing hormone
antagonize
pharmaceutical composition
produce
Prior art date
Application number
BR9911564-6A
Other languages
English (en)
Inventor
Shuichi Furuya
Nobuo Choh
Nobuhiro Suzuki
Takashi Imada
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR9911564A publication Critical patent/BR9911564A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Abstract

"COMPOSTO, PROCESSO PARA PRODUZIR UM COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA ANTAGONIZAR O HORMÈNIO DE LIBERAçãO DE GONADOTROPINA EM UM MAMìFERO, E, USO DE UM COMPOSTO" O composto da presente invenção possui excelente atividade de antagonização do hormónio de liberação de gonadotropina, e é útil para evitar doenças dependentes de hormónio sexual, por exemplo, canceres dependentes de hormónio sexual (por exemplo, câncer prostático, câncer uterino, câncer de mama, tumor pituitário) hipertrofia prostática, histeromioma, endometriose, puberdade precoce, síndrome de amenorréia, síndrome ovariana multiocular, pústulas, etc., ou como um regulador de gravidez (por exemplo, contraceptivo), remédio para a infertilidade ou regulador de menstruação.
BR9911564-6A 1998-06-26 1999-06-24 Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto BR9911564A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18126398 1998-06-26
JP33300498 1998-11-24
PCT/JP1999/003379 WO2000000493A1 (en) 1998-06-26 1999-06-24 Thienopyridine compounds, their production and use

Publications (1)

Publication Number Publication Date
BR9911564A true BR9911564A (pt) 2001-10-09

Family

ID=27308836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911564-6A BR9911564A (pt) 1998-06-26 1999-06-24 Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto

Country Status (9)

Country Link
US (1) US6262267B1 (pt)
EP (1) EP1090010A1 (pt)
AU (1) AU4393199A (pt)
BR (1) BR9911564A (pt)
CA (1) CA2331399A1 (pt)
HU (1) HUP0102805A3 (pt)
NO (1) NO20006479D0 (pt)
SK (1) SK19752000A3 (pt)
WO (1) WO2000000493A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4066552B2 (ja) * 1999-03-16 2008-03-26 コニカミノルタビジネステクノロジーズ株式会社 画像形成装置
US20040023987A1 (en) * 2000-06-14 2004-02-05 Yoshio Hata Sustained release compositions
AU2001288102A1 (en) * 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
CA2481391A1 (en) * 2002-04-12 2003-10-23 Takeda Pharmaceutical Company Limited Preventives/remedies for hotflash
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
BRPI0413876A (pt) * 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
EP0781774B1 (en) * 1995-12-08 2002-07-31 Takeda Chemical Industries, Ltd. Prolactin production inhibitory agents
AU2406597A (en) * 1996-04-26 1997-11-19 Takeda Chemical Industries Ltd. Thienopyridine derivatives, their production and use

Also Published As

Publication number Publication date
AU4393199A (en) 2000-01-17
EP1090010A1 (en) 2001-04-11
HUP0102805A2 (hu) 2001-11-28
WO2000000493A1 (en) 2000-01-06
NO20006479L (no) 2000-12-19
SK19752000A3 (sk) 2001-08-06
CA2331399A1 (en) 2000-01-06
US6262267B1 (en) 2001-07-17
NO20006479D0 (no) 2000-12-19
HUP0102805A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
Ben-Josef et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)
ATE215081T1 (de) Gonadotropin releasing hormon- antagonisten
BR112014017483A2 (pt) derivados de espiroindolina e composições farmacêuticas dos mesmos
MXPA03001320A (es) Agentes no peptidicos de la gnrh, composiciones farmaceuticas y procedimientos para su uso.
MXPA02010066A (es) Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos.
PE9899A1 (es) Progesterona para tratar o reducir isquemia
BR9911564A (pt) Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto
AR036337A1 (es) Composicion farmaceutica inyectable que comprende un peptido antagonista de gnrh, un conjunto farmaceutico, metodo de tratamiento y uso de un peptido antagonista de gnrh.
AU2003255820A8 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
Balasch et al. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot
NO20005145L (no) FremgangsmÕte for behandling av fertilitetsproblemer
TW430665B (en) Thienopyridine compounds for antagonizing gonadotropin-releasing hormone and their production
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
DE602004030546D1 (de) LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers.
Lövgren et al. Binding characteristics of estrone, estradiol and estriol to the human myometrial estrogen receptor
Vargas Jr Attempt to induce formation of fibroids with estrogen, in the castrated female rhesus monkey
Lo et al. Gonadoblastoma in patient with Turner's syndrome
MA38463A1 (fr) Dérivés de spiroindoline pour une utilisation en tant qu'antagonistes du récepteur de l'hormone de libération des gonadotrophines
DE60122575D1 (de) 7-HETEROCYCLYL-SUBSTITUIERTE CHINOLIN- UND THIENOi2,3-BöPYRIDIN-DERIVATE ALS ANTAGONISTEN DES GONADOTROPIN-FREISETZENDEN HORMONS
Vollmer et al. Androgen ablation induces tenascin expression in the rat prostate
PE20020894A1 (es) USO DE LIGANDOS SELECTIVOS PARA ERß PARA REGULAR LA FERTILIDAD
Ramakrishnan et al. Progesterone levels in monkeys immunized with Pr-β-hCG-TT after injection of hLH and hCG during luteal phase
Chen et al. Effects of raloxifene at two different doses for ovulation induction on endometrial pinopodes in mice during the implantation window
Schmidt Nuclear and cytosol androgen receptor in androgen dependent dermatoses in female patients
Mor et al. Sex hormones, apoptosis and the fas/fas ligand system in normal endometrial tissue remodeling

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]